How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Nosocomial Infections Market
- By Infection Type: Surgical Site Infections (SSI), Catheter-Associated Urinary Tract Infections (CAUTI), Central Line-Associated Bloodstream Infections (CLABSI), Ventilator-Associated Pneumonia (VAP), Clostridium difficile Infections (CDI)
- By Pathogen: Gram-positive Bacteria, Gram-negative Bacteria, Fungi, Viruses, Multidrug-Resistant Organisms (MDROs)
- By Product Type: Disinfectants and Antiseptics, Sterilization Equipment, Diagnostic Kits, Antimicrobial Drugs, Infection Control Devices
- By End User: Hospitals, Ambulatory Surgical Centers, Long-term Care Facilities, Diagnostic Laboratories, Home Healthcare Settings
- By Prevention and Control Method: Hand Hygiene Products, Environmental Cleaning Solutions, Surveillance and Monitoring Systems, Antimicrobial Stewardship Programs, Isolation and Barrier Precautions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Site Infections (SSI) leads By Infection Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Nosocomial Infections Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →3M Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ecolab Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →SteriPack Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Getinge AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Advanced Sterilization Products (ASP) - Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cantel Medical Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bioquell
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mölnlycke Health Care
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cardinal Health Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →STERIS Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →ConvaTec Group PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Medline Industries Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Kimberly-Clark Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Site Infections (SSI)52.0
- Catheter-Associated Urinary Tract Infections (CAUTI)14.0
- Central Line-Associated Bloodstream Infections (CLABSI)15.0
- Ventilator-Associated Pneumonia (VAP)11.3
- Clostridium difficile Infections (CDI)7.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- 3M Company17.7
- Ecolab Inc.19.5
- Becton11.0
- Dickinson and Company (BD)9.4
- Thermo Fisher Scientific Inc.6.8
- SteriPack Group7.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.6
- Europe22.6
- Asia Pacific20.0
- Latin America12.7
- Middle East and Africa10.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| 3M Company | 91 | 91 | 78 | 77 | 73 | 97 | 85 |
| Ecolab Inc. | 74 | 73 | 85 | 74 | 78 | 82 | 78 |
| Becton | 71 | 75 | 73 | 84 | 75 | 70 | 75 |
| Dickinson and Company (BD) | 61 | 72 | 77 | 67 | 58 | 80 | 69 |
| Thermo Fisher Scientific Inc. | 65 | 57 | 57 | 56 | 76 | 70 | 64 |
| SteriPack Group | 67 | 60 | 51 | 69 | 69 | 68 | 64 |
| Getinge AB | 53 | 53 | 63 | 52 | 47 | 44 | 52 |
| Advanced Sterilization Products (ASP) - Johnson & Johnson | 50 | 56 | 49 | 38 | 37 | 36 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- 3M Company
- Ecolab Inc.
- Becton
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| 3M Company | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Ecolab Inc. | ◐ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Becton | − | ✓ | ✓ | ◐ | ◐ | ◐ |
| Dickinson and Company (BD) | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Thermo Fisher Scientific Inc. | − | ◐ | ◐ | ◐ | ✓ | ◐ |
| SteriPack Group | ✓ | ◐ | − | ◐ | ◐ | − |
| Getinge AB | − | − | ✓ | ◐ | − | − |
| Advanced Sterilization Products (ASP) - Johnson & Johnson | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Infection Type in North America, then scale across Nosocomial Infections Market — a $313M beachhead inside a $5.13B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Surgical Site Infections (SSI)
Best fit — highest urgency & budget in Infection Type.
Catheter-Associated Urinary Tract Infections (CAUTI)
Strong fit — clear ROI and a fast path to value.
Central Line-Associated Bloodstream Infections (CLABSI)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Infection Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Pathogen & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Product Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Infection Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Nosocomial Infections Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Nosocomial Infections Market is a high-growth opportunity — $8.61B by 2033, compounding at 11.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.6% CAGR
Demand compounds through 2033, outpacing GDP across Infection Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Infection Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Pathogen optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Nosocomial Infections Market — a $8.19B market by 2033. Plan: grow share from 7.8% to 14.1%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 14.1% | At risk |
| Revenue | $599M | $1.15B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 37.8% | 45.3% | At risk |
| Customer retention | 87.9% | 95.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Infection Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Pathogen capability
A defensible second engine — invest in Pathogen to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Infection Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Pathogen
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $154M capacity & capability investment
- Greenlight bolt-on M&A in Pathogen
- Authorise North America expansion plan
- Fund R&D program for Infection Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentOn track
Sales deck · value proposition
Win the Nosocomial Infections Market conversation — a $7.89B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Infection Type
Goal Grow share in Infection Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Nosocomial Infections Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Nosocomial Infections Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →NoSQL Databases Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportNotch Board Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportNotching Machine Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportNote Market
Market size, share, segmentation and regional forecast.
$363M market · 2025 base year
View reportNotebook Computer Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportNotebook Pcs Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportNotebook Speaker Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportNotebook Touch Pad Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportNotebooks and Diaries Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportNotepad Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportNote-Taking Apps and Text Editors Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportNote-taking or Inking Software Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy